RRR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy RRR now. Price is sitting just above a key pivot/support zone (~61.95) with neutral-to-improving momentum, strong YoY earnings growth, and a clearly improving Street stance (multiple target raises and Buy/Overweight ratings). While options flow shows unusually heavy put volume (near-term caution/hedging into earnings), the setup still favors an immediate entry for an impatient buyer looking for upside over the next several weeks into the Feb-10 earnings catalyst.
Trend/Setup: RRR is in a consolidation phase near the pivot (61.95) with converging moving averages, suggesting a coiled move rather than a mature trend. Momentum: MACD histogram at -0.153 (below zero) but negatively contracting implies downside momentum is fading. RSI: RSI(6) 54.14 = neutral, consistent with basing rather than overbought conditions. Key levels: Support S1 60.50 (then S2 59.61). Resistance R1 63.40 (then R2 64.29). A push/hold above ~63.40 would confirm a breakout attempt; failure below ~60.50 would weaken the near-term long thesis. Pattern-based forward bias: Similar-pattern stats indicate ~50% probability of gains, with modeled upside of ~+4.5% next day, +6.88% next week, +9.77% next month.
Intellectia Proprietary Trading Signals
shows strong profit growth (Net Income +45.95% YoY, EPS +41.67% YoY) despite modest revenue growth, indicating margin/operating leverage benefits.
signals traders are positioned defensively in the near term.
Latest quarter: 2025/Q3. Growth: Revenue 475.572M (+1.61% YoY) = modest top-line expansion. Profitability: Net income 42.254M (+45.95% YoY) and EPS 0.68 (+41.67% YoY) = strong earnings acceleration. Margins: Gross margin 51.89% (+2.43% YoY) = improving efficiency/pricing mix. Overall read: A quality quarter driven by margin/profit expansion, supportive of a buy thesis going into the next report.
Recent trend: Ratings skew positive and price targets have been moving up into early 2026. Notable changes: JPMorgan to $66 (Overweight), Barclays to $69 (Overweight), BofA to $65 (Neutral), Morgan Stanley to $60 (Equal Weight), Jefferies raised to $73 (Buy) and previously upgraded to Buy; Citi initiated Buy at $63; Wells Fargo initiated Equal Weight at $58. Wall Street pros: Attractive Las Vegas locals exposure, high barriers to entry/stable regulation, and a visible capital project pipeline that can add EBITDA over time. Wall Street cons: Some view shares as closer to fully valued, with muted sector fundamentals and consumer sensitivity; development-related disruption and estimate revision risk remain key debate points. Influential/political trading: No recent congress trading data available; hedge funds and insiders show neutral recent activity.
